Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
NCT06496243
Recruiting
The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib/evolocumab Patients will: Have baseline Lp(a) tested at randomization Take 10mg/dL obiceptrapib daily for 8 weeks and have Lp(a) tested at Week 8 Take 10 mg/dL obicetrapib daily/evolocumab 140 every other week for 8 weeks and have Lp(a) retested at Week 16
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/31/2025
Locations: UPenn, Philadelphia, Pennsylvania
Conditions: Dyslipidemias
Register for Updates
H. Pylori Eradication With Argon Plasma During Endoscopy
NCT06529159
Recruiting
The objective of the study is to investigate the efficacy and safety of an argon plasma-based therapy - HEAPE - in treating H. pylori infections during endoscopic procedures. By filling the stomach with sodium chloride solution that is treated with APC (PAL), the Investigators hypothesize a significant reduction in H. pylori. The use of PAL instead of direct application of APC allows for a broader and more homogeneous application throughout the stomach and a faster procedure time, as the fluid b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Helicobacter Pylori Infection, Helicobacter Pylori, Helicobacter Pylori Gastrointestinal Tract Infection, H. Pylori Infection, H. Pylori Gastrointestinal Disease
Register for Updates
Marginal Ulcer Healing With Low-Thermal Argon Plasma Endoscopic Treatment
NCT06543316
Recruiting
The objective of the study is to investigate the treatment of marginal ulcers with Low Thermal plasma in an endoscopic setting. By a treatment of the ulcerated areas with argon plasma with low power settings (\~ 1 W) we hypothesize that the size of the ulcers will shrink, and the healing is accelerated compared to standard of care alone. Patients will benefit from this minimally invasive approach compared to a much more invasive surgical approach that comes with higher risks and hospital stay le... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Roux-en-y Anastomosis Site, Marginal Ulcer, Marginal Ulcer (Peptic) or Erosion, Ulcer, Ulcer, Gastric, Ulcer Gastrointestinal, Abdominal Pain, Nausea, Vomiting, GastroIntestinal Bleeding, Dysphagia, Ulcer Gastrojejunal
Register for Updates
Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder
NCT06545916
Recruiting
The purpose of this study is to evaluate the efficacy of sunobinop compared to placebo on alcohol consumption in subjects with alcohol use disorder.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Belmont Medical Office, Brooklyn, New York +5 locations
Conditions: Alcohol Use Disorder
Register for Updates
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076
Recruiting
The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Total Dermatology, Birmingham, Alabama +277 locations
Conditions: Plaque Psoriasis
Register for Updates
Screening, Evaluation and Assessment (SEA) Protocol at the NIDA IRP
NCT06552741
Recruiting
Background: People who will participate in research studies need to undergo proper screening, evaluation, and assessment (SEA). SEA helps keep those who participate in studies safe. It also helps ensure accurate study results. The National Institute on Drug Abuse (NIDA) Intramural Research Program (IRP) wants to screen people with alcohol and/or substance use disorders (ASUD) as well as people without ASUD for ongoing studies at NIDA in Baltimore, MD Objective: To screen people with or withou... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/31/2025
Locations: National Institute on Drug Abuse, Baltimore, Maryland
Conditions: Substance Use Disorder, Alcohol Use Disorder
Register for Updates
Necrosectomy With Cryotechnology for Accelerated Removal
NCT06553651
Recruiting
Pancreatic necrosis is a serious complication of acute pancreatitis. Pancreatic necrosis involves the irreversible death of pancreatic tissue, which can lead to severe health issues, including infections and an increased risk of death. An endoscopic procedure called direct endoscopic necrosectomy (DEN) is typically performed to remove this necrotic pancreatic tissue as a minimally invasive treatment. This procedure is performed using a thin, flexible, lighted tube called an endoscope and endosco... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Pancreatic Necrosis, Acute Pancreatitis, Acute Pancreatic Necrosis, Necrosis, Necrosis Pancreas, Walled-Off Pancreatic Necrosis
Register for Updates
Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy.
NCT06564974
Recruiting
The goal of this observational study is to follow patients being treated with the FDA approved drug AGAMREE® in male patients 2 years of age or older with Duchenne's Muscular Dystrophy for long term safety and quality of life.
Gender:
MALE
Ages:
2 years and above
Trial Updated:
07/31/2025
Locations: Phoenix Children's Hospital, Phoenix, Arizona +24 locations
Conditions: Duchenne Muscular Dystrophy
Register for Updates
Diabetic Foot Ulcer (DFU) Rapid Pathogen Identification
NCT06569238
Recruiting
The purpose of this study is to evaluate the role of rapid diagnosis of pathogens in treatment of infection and wound healing in diabetic foot ulcers. This research is studying the use of a new device of people to learn if metagenomic next generation sequencing (mNGS) techniques technology is a feasible tool that can be used to direct targeted antibiotic therapy in infected diabetic foot ulcers. Participant's tissue will be randomized to usual care tissue collection and cultures (standard of ca... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: University of Michigan, Ann Arbor, Michigan +1 locations
Conditions: Diabetic Foot Ulcer, Diabetes Mellitus, Wound
Register for Updates
Transference of Established Simulated Skills (TEST) Trial
NCT06572033
Recruiting
This study aims to determine if skills learned in the simulation lab, specifically in managing mask leak during positive pressure ventilation (PPV), translate effectively to the delivery room. By comparing the performance of healthcare providers on mannequins in the lab to their performance on newborns in the delivery room, the study seeks to establish a Ventilation Performance Score (VPS) based on data from a respiratory function monitor. The primary hypothesis is that a provider's ability to m... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/31/2025
Locations: Parkland Memorial Hospital, Dallas, Texas
Conditions: Neonatal Respiratory Distress
Register for Updates
A Pilot rTMS Trial for Neuropsychiatric Symptoms of Long-COVID
NCT06586398
Recruiting
This is a pilot randomized trial of rTMS for symptoms of fatigue and brain fog, and other neuropsychiatric symptoms of Long-COVID (Post-COVID, post-acute sequelae of COVID-19 infection, PASC). Twenty participants diagnosed with Long-COVID and recruited from the UCLA Long-COVID clinic will be randomized to receive active rTMS versus sham stimulation for 15 treatments followed by another 15 open-label rTMS treatments. Investigators will compare the safety and tolerability of rTMS vs Sham and exami... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: UCLA Semel Institute, Los Angeles, California
Conditions: Long Covid-19, PASC Post Acute Sequelae of COVID 19, Brain Fog, Fatigue
Register for Updates
A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
NCT06592638
Recruiting
This is a multi-center, open-label, Phase 1 clinical study of ZG006 in the US for the treatment of subjects with small cell lung cancer who have failed or are intolerant to available standard treatment. During the dose escalation stage, a standard "3+3" design will be used to assess the MTD/ recommended dose for the subsequent studies.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/31/2025
Locations: Zelgen Site 105, Orange, California +5 locations
Conditions: Small Cell Lung Cancer
Register for Updates